218 patents
Page 10 of 11
Utility
Cyclopropylamines as LSD1 inhibitors
8 Jun 20
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Wenqing Yao
Filed: 3 May 18
Utility
Heterocyclic compounds as immunomodulators
1 Jun 20
Liangxing Wu, Jingwei Li, Wenqing Yao
Filed: 28 Mar 19
Utility
Aminopyrazine diol compounds as PI3K-γ inhibitors
1 Jun 20
Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao
Filed: 6 Mar 19
Utility
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
18 May 20
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
Filed: 18 Jun 19
Utility
Heterocyclylamines as PI3K inhibitors
11 May 20
Yun-Long Li, Wenqing Yao, Andrew P. Combs, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks
Filed: 18 Jun 19
Utility
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
4 May 20
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
James D. Rodgers, Stacey Shepard
Filed: 31 Oct 18
Utility
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
4 May 20
James D. Rodgers, Stacey Shepard, Lixin Shao, Joseph Glenn
Filed: 26 Jul 18
Utility
Imidazopyridines and imidazopyrazines as LSD1 inhibitors
4 May 20
Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
Filed: 17 Jul 18
Utility
Bicyclic heterocycles as FGFR4 inhibitors
27 Apr 20
Alexander Sokolsky, Liangxing Wu, Wenqing Yao
Filed: 14 Feb 19
Utility
Salts of TAM inhibitors
27 Apr 20
The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.
Zhongjiang Jia, Yongzhong Wu, Yongchun Pan, Jiacheng Zhou, Qun Li
Filed: 25 Sep 18
Utility
Crystalline solid forms of a BET inhibitor
20 Apr 20
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 6 Dec 18
Utility
Tricyclic heterocycles as BET protein inhibitors
13 Apr 20
The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Richard B. Sparks
Filed: 31 Jan 19
Utility
Heterocyclic compounds as immunomodulators
13 Apr 20
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 9 May 19
Utility
Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
6 Apr 20
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Hui-Yin Li, James D. Rodgers
Filed: 7 Jun 18
Utility
Crystalline forms of a FGFR inhibitor and processes for preparing the same
6 Apr 20
The present disclosure relates to solid forms of N-{[2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-6′-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
Zhongjiang Jia, Qun Li
Filed: 24 May 18
Utility
Low dose combination therapy for treatment of myeloproliferative neoplasms
23 Mar 20
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.
Holly Koblish, Gary Reuther
Filed: 6 Dec 18
Utility
Aza-heteroaryl compounds as PI3K-gamma inhibitors
23 Mar 20
Ge Zou, Andrew P. Combs
Filed: 27 Jun 18
Utility
Sustained release dosage forms for a JAK1 inhibitor
17 Feb 20
This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
Krishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
Filed: 17 May 17
Utility
Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
10 Feb 20
Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
Filed: 12 Sep 18
Utility
Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors
30 Dec 19
The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use.
Chu-Biao Xue, Yun-Long Li, Hao Feng, Ke Zhang
Filed: 10 Mar 19